Form 4: United Therapeutics Director Ray Kurzweil Reports Stock Option and Restricted Stock Unit Awards

Director Ray Kurzweil reports the acquisition of stock options and restricted stock units in United Therapeutics Corporation.

Summary

• Ray Kurzweil, a director of United Therapeutics Corporation, filed a Form 4 on July 26, 2024, reporting transactions related to the company's stock.
• On July 25, 2024, Kurzweil acquired 1,440 stock options with an exercise price of $336.37, which vest on July 25, 2025, and expire on July 25, 2034.
• Additionally, Kurzweil acquired 590 restricted stock units (RSUs), each representing the right to receive one share of United Therapeutics common stock upon vesting, also vesting on July 25, 2025.
• Following these transactions, Kurzweil directly owns 1,440 stock options and 590 restricted stock units.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a routine transaction. The granting of equity can be seen as a positive sign of aligning management interests with shareholders, but it's a standard practice.

Positives

• The granting of stock options and restricted stock units to a director aligns their interests with those of the shareholders.
• The vesting period of one year encourages the director's continued service and contribution to the company.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which is common in publicly traded companies. It provides transparency regarding the compensation and ownership stakes of company directors.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders by aligning the director's interests with the company's performance.

Key Dates